Recombinant Cynomolgus LTBR protein, hFc-tagged
Cat.No. : | LTBR-8827C |
Product Overview : | Recombinant Cynomolgus LTBR protein(F6V995)(Met1-Met225), fused with hFc tag, was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
Source : | HEK293 |
Species : | Cynomolgus |
Tag : | hFc |
Form : | Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA. |
Molecular Mass : | The recombinant cynomolgus LTBR is a disulfide-linked homodimer. The reduced monomer comprises 439 amino acids and has a calculated molecular mass of 48.8 KDa. The apparent molecular mass of the protein is approximately 64-70 KDa respectively in SDS-PAGE. |
Protein Length : | Met1-Met225 |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method |
Purity : | > 85 % as determined by SDS-PAGE |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
Products Types
◆ Recombinant Protein | ||
LTBR-369H | Recombinant Human LTBR Protein, Fc-tagged | +Inquiry |
Ltbr-1751M | Recombinant Mouse Ltbr Protein, His-tagged | +Inquiry |
LTBR-1752H | Recombinant Human LTBR Protein, His&GST-tagged | +Inquiry |
LTBR-4589H | Recombinant Human LTBR Protein, GST-tagged | +Inquiry |
LTBR-1288R | Recombinant Rat LTBR protein(Met1-Ala218), hFc-tagged | +Inquiry |
◆ Lysates | ||
LTBR-1229CCL | Recombinant Cynomolgus LTBR cell lysate | +Inquiry |
LTBR-1052RCL | Recombinant Rat LTBR cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionTherapeutic strategies targeting LTBR include inhibition of its signaling pathways, modulation of immune response, and anti-cancer approaches. Inhibitors of the NF-κB pathway, such as small molecule inhibitors or neutralizing antibodies, can be used to block LTBR-mediated signaling and reduce inflammation or tumor growth.
Current research on LTBR aims to further elucidate its role in disease mechanisms, particularly in autoimmune disorders, chronic inflammation, and cancer. Studies are investigating the downstream effects of LTBR activation, its involvement in immune cell function, and the identification of potential therapeutic targets within the LTBR signaling pathway.
The expression of LTBR is regulated by transcription factors and signaling pathways. For example, NF-κB and AP-1 transcription factors can bind to the promoter region of LTBR gene and enhance its expression. Additionally, cytokines and growth factors can also influence LTBR expression through downstream signaling cascades.
The LTBR signaling pathway interacts with various other signaling pathways, including those activated by TNFR1, TNFR2, and CD40. These interactions can lead to crosstalk and amplification of signaling, resulting in enhanced cellular responses. Understanding these interactions is crucial for elucidating the complex network of signaling events involved in disease pathogenesis.
LTBR, a membrane protein belonging to the tumor necrosis factor receptor superfamily, regulates various cellular processes such as inflammation, immune response, and lymphoid organ development. It activates signaling pathways including the NF-κB pathway and non-canonical NF-κB pathway.
Yes, certain genetic variants have been identified that are associated with altered LTBR expression and disease susceptibility. These variants can affect the binding of transcription factors or alter the stability of LTBR mRNA, leading to dysregulation of LTBR expression and increased risk of certain diseases.
Future research directions in LTBR include exploring the molecular mechanisms underlying LTBR-mediated signaling, investigating the impact of LTBR genetic variants on disease susceptibility, and developing novel therapeutic strategies targeting LTBR. Additionally, studying the interplay between LTBR and other signaling pathways may uncover new insights into disease pathogenesis and identify new therapeutic avenues.
Customer Reviews (3)
Write a reviewUnrivaled in efficiency, this innovative elixir leaves me awestruck.
By using this reagent, I can better investigate protein interactions.
The interpretation of the results provided by this reagent is clear, allowing me to better understand the experimental outcomes.
Ask a Question for All LTBR Products
Required fields are marked with *
My Review for All LTBR Products
Required fields are marked with *
Inquiry Basket